BofA initiated coverage of Metsera (MTSR) with a Buy rating and $38 price target implying over 20% share upside. Metsera is a clinical-stage ...

Guggenheim initiated coverage of Metsera (MTSR) with a Buy rating and $56 price target The firm sees a “highly promising multi-billion ...

New research finds older women achieve the best results with weight loss injections – thanks to consistent tracking and ...

While the outcomes can be positive, Consumer Reports warns there are important considerations, especially for older adults, ...

Weight loss drugs like Ozempic bring health gains, but at what costs to relationships? Couples must face new challenges as ...

Even a little weight loss can work wonders for your health. A study found that people at high risk for developing type 2 diabetes who lost 5 to 7 percent of their weight had a 58% lower risk of ...

Aardvark Therapeutics has followed up filings and speculation with a $94 million initial public offering, putting itself on ...

10 Stocks to Sell NOW! 3 Stocks to DOUBLE This Year The 10 Best Stocks to Own in 2023 7 Stocks to Buy and Hold Forever Alongside the amended certificate, Metsera, Inc. also updated its bylaws.

Learn more Cats can lose weight safely with one of the best weight loss foods for cats. These foods typically are lower in calories and fat and contain more nutrients per serving than other formulas.

To lose weight, you need to be in a calorie deficit. However, it's not as simple as consuming fewer calories. Depending on your physical activity, age, calories burned and more factors ...

NEW YORK, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Metsera, Inc. (Nasdaq: MTSR) ("Metsera”), a clinical-stage biotechnology company developing next-generation injectable and oral nutrient stimulated hormone ...